Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by cartach13on Jul 21, 2009 3:55am

327 Views

Post# 16152820

RE: Why are we lagging?

Was HUMAN GENOME in Phase lll trials? If so this would explain pop in SP would'nt it? Previous poster indicated that ONC application for Phase lll trails was submitted in April. Once that is approved [gotta be positive here] , then we'll see a significant increase in SP. As a long time holder of ONC I can remember the SP above $10 for a short time and it will get there again.

Bullboard Posts

Morning Market Outlook for Sept. 19, 2024